Pharmacological treatments designed to reactivate fetal γ-globin can lead to an effective and successful clinical outcome in patients with hemoglobinopathies. However, new approaches remain highly desired because such treatments are not equally effective for all patients, and toxicity issues remain. We have taken a systematic approach to develop an embedded chimeric peptide nucleic acid (PNA) that effectively enters the cell and the nucleus, binds to its target site at the human fetal γ-globin promoter, and reactivates this transcript in adult transgenic mouse bone marrow and human primary peripheral blood cells. In vitro and in vivo DNAbinding assays in conjunction with live-cell imaging have been used to establish and optimize chimeric PNA design parameters that lead to successful gene activation. Our final molecule contains a specific γ-promoter-binding PNA sequence embedded within two amino acid motifs: one leads to efficient cell/nuclear entry, and the other generates transcriptional reactivation of the target. These embedded PNAs overcome previous limitations and are generally applicable to the design of in vivo transcriptional activation reagents that can be directed to any promoter region of interest and are of direct relevance to clinical applications that would benefit from such a need.
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γ-globin gene reactivation | primary human CD34+ cells T he correct regulation of gene expression is required for fundamental processes in differentiation and development (1) . In a number of these cases, the transcriptional onset and decline of a series of closely related genes are tightly and sequentially controlled, a process that is critical for attaining the correct genotypic readout and proper phenotypic effect (2) (3) (4) . A particularly wellstudied example of this process is the developmental control of the hemoglobin proteins, particularly those encoded by the genes within the ß-like globin locus (5, 6) . These variants exhibit a sequential erythroid-restricted pattern of expression during development, beginning with the yolk sac ϵ-globin, switching to the fetal γ-globin, and ending with the adult ß-globin.
The critical requirement for correct regulation of this locus is demonstrated by the moderate to life-threatening clinical manifestations exhibited by the ß-thalassemias. β-thalassemia is primarily caused by mutations in the β-globin gene that lead to reduced or complete loss of β-globin expression. Along with other hemoglobinopathies (such as sickle cell disease), they give rise to the most common single gene genetic disorder worldwide (7) . Pharmacological reactivation of the silent fetal (γ) globin chain provides a therapeutic benefit to these patients by compensating for absent adult β-globin chains (in ß-thalassemia) (7) or by interfering with the polymerization of mutant hemoglobins (in sickle cell disease) (8) ; however, these are not always free from complications (9) . As a result, there remain compelling reasons to search for approaches and reagents that achieve reactivation with low toxicity and high penetrance.
Peptide nucleic acids (PNAs) are oligonucleotide analogues in which the phosphodiester backbone of DNA is replaced by an achiral uncharged polyamide backbone (10) . They are true DNA mimics, because they form Watson-Crick bonds with DNA and RNA, but are of higher thermal stability than natural duplexes due to the lack of electrostatic repulsion (11) . They are also resistant to proteases and nucleases, and thus afford a significantly greater biological stability in culture and in vivo (12) . A unique aspect of PNAs is that amino acids can be covalently added to the peptide backbone at either end of the sequence of bases. Of particular relevance for the present studies, the PNA/DNA interaction may occur through single-strand invasion (11, 13) . In this case the PNA, which can be of mixed sequence design, hybridizes with one strand of DNA through Watson-Crick base pairing and simply replaces the other strand of the double helix. This singlestrand design avoids the sequence limitations and modified base requirements inherent in PNA molecules that are based on a "clamp" or "bisPNA" structure design that binds DNA through triple helical (Hoogsteen) base paring (PNA/DNA/PNA).
PNA molecules are thus promising candidates for clinical use as agents to modulate gene expression. For the most part, PNAs have been used as an antigene agent (14-17), because they have the capacity for down-regulating gene expression in cultured cells and in animals. In addition, PNAs have been modified to maximize cellular/nuclear entry in order to increase the efficiency for in vivo applications (15, 18, 19) . However, currently there is no established PNA conjugated system that combines these varied modifications and has been demonstrated to stably and efficiently enter, target, and transcriptionally activate an endogenous chromosomal locus in living cells.
Our interest here is to utilize PNA molecules to alter expression of the ß-like globin locus. We have successfully designed PNAs conjugated to cell/nuclear entry and transcription activation domains that stably and efficiently enter and target the γ-globin gene promoter. We further demonstrate that this "embedded" chimeric PNA molecule reactivates endogenous expression of the fetal γ-globin gene in adult transgenic murine bone marrow or adult human CD34 þ cells, making them of immediate use for treatment of hemoglobinopathies and also of more general relevance to clinical applications that require targeted activation of gene expression for alleviation of disease.
Results PNA78 Has the Best Target Binding Specificity in Vitro. We designed four 12-to 15-mer single-strand PNAs (11) that correspond to the γ-globin promoter at positions −150, −116, −78, and −7 relative to the transcription start site (Fig. 1A) . In order to facilitate their solubility and cellular uptake, we also attached a lysine residue to the 3′ end to give the PNA molecule a positive charge and polarity. Such a design has the added advantage of enhancing strand invasion (13) . For visual monitoring purposes, a biotin residue was linked to the 5′ ends of all four PNAs.
To examine the binding specificity of the four PNAs to their target sequences, an in vitro magnetic pull-down assay was developed (Fig. 1B) . Double-stranded DNA oligos containing specific or point-mutated PNA target sequences were labeled with 32 P and incubated with varying amounts of individual cognate PNAs, followed by streptavidin-conjugated magnetic bead pull-down. The radioactivity of the pull-down product was then measured by scintillation counter. We find that the ability of each PNA to bind and discriminate between wild-type and mutant oligos varies considerably. In the present tests, PNA150 or PNA7 do not discriminate or bind well to their target sites under these conditions. However, PNA116 and PNA78 bind their target DNA oligo in proportion to their input. Even though PNA116 has the best recovery rate of its wild-type DNA target, it also binds the mutant DNA target to an unacceptable extent. On the other hand, PNA78 exhibits the best discrimination (∼25-fold) and specificity in recognizing its target sequence.
To further confirm this observation, permanganate (KMnO 4 ) probing of the PNA78/DNA interaction in solution was carried out (Fig. 1C) . When PNA perturbs the double-strand DNA structure, one strand of DNA is exposed and sensitive to KMnO 4 oxidation (20) . The results demonstrate that PNA78 binds specifically to its target region within the γ-globin promoter fragment, with residues at the 5′ end of its interaction most accessible to chemical cleavage. Based on all the in vitro studies, we utilized PNA78 for the remainder of our experiments.
Cellular and Nuclear Localization of PNA. Unmodified and slightly modified PNAs have been successfully delivered directly to cells without the use of transfection reagents and protocols (21, 22) . To test for entry into an erythroid cell, we incubated varying amounts of PNA78 for different lengths of time with K562 cells and monitored entry and localization by fluorescent microscopy after incubation with streptavidin-FITC. K562 cells are human erythroid leukemia cells that display similar characteristics of fetal erythrocytes because they express high levels of gamma globin and no or very low levels of beta globin (23) . We find that PNA efficiently (over 90%) enters cells after a simple overnight incubation in growth media with an optimal concentration of 10 μM (Fig. S1A ) but with no evidence of nuclear entry.
The highly positive charged protein transduction domain of the transactivator of transcription (TAT) sequence (YGRJJR-RQRRR) from HIV-1 has been shown to facilitate peptide delivery to the cell and even to the nucleus by an energy-and receptor-independent mechanism called macropinocytosis (24) . Because all cells are active in macropinocytosis, the efficiency is normally quite high and occurs rapidly. However, standard fixation methods cannot be applied to the analysis of TAT internalization (25) . In light of this, we linked PNA78 at its 3′ end to the D-isomer form (26) either of the TAT sequence or of a nuclear localization signal (NLS) (15) and monitored localization in live (i.e., unfixed) COS7 or poly-L-lysine-attached K562 cells to help us more easily detect subcellular localization ( Fig. S1 B and C) . These results show that, after only a 2-h incubation, the conjugated PNA molecules not only enter the cells but also proceed to the nucleus; however, the distribution and efficiency is significantly higher in PNA78/TAT treated K562 cells. Efficiencies of cell entry are always greater than 50% and sometimes approach 95%. Based on these experiments, we conclude that PNA molecules attached to a TAT sequence at its 3′ end provide us with a consistent and efficient means of directing the PNA cargo to the nucleus.
Detection of in Vivo Target Binding of PNA78 in K562 Cells Using a
Chromatin Association Assay. A BLASTN search with the 15-mer PNA78 sequence reveals 11 homologous hits within the human genome (Table S1 ). None of these are closer than 85 kB to the nearest gene except for the single sites within the Aγ-and Gγ-globin promoters that formed the basis for our design. As a result, we next addressed whether PNA78 can interact with its γ-globin target site in vivo by developing a modification of the chromatin immunoprecipation assay. As we cannot use antibodies, we took advantage of the biotin label already incorporated into the PNA molecule. We devised a unique application of the standard ChIP Fig. 1 . In vitro target binding specificity of four PNAs designed to interact with the human γ-globin promoter. (A) PNA150, PNA116, PNA78, and PNA7 were designed to target the proximal promoter region (−202 to þ33) of the human fetal γ-globin gene at specific sites indicated by the filled in boxes. The relative location of known promoter elements within this region are also indicated. Orientation of the PNA molecule relative to the promoter sequence is shown above, with a lys at its 3′-end and a biotin molecule (circle) attached at the 5′-end. (B) Different concentrations of PNAs (0-10 μM) were incubated with a constant amount of radioactively labeled DNA oligonucleotide (10 nM) containing either the wild type (WT) or mutated (mut) target sequence followed by incubation with streptavidin Dynabeads and collection with a magnetic particle concentrator. Bound∕input ratios were obtained after scintillation counter analysis. (C) Permanganate probing confirms the specificity of PNA78 by showing that oxidized and cleaved T bases (lane 3) are accessible within the designated target sequence compared to 'no PNA' (dashed line) and PNA7 (as noninteracting PNA) controls. The A+G sequence ladder is shown in lane 1, along with the nucleotide sequence of the γ-globin promoter aligned on the left. assay whereby streptavidin-magnetic beads (rather than antibodies) are used to pull down the PNA78/DNA complex after the normal series of PNA/cell incubation, cross-linking, and chromosomal DNA shearing steps ( Fig. 2A) . Along with the "no addition" negative control, we also synthesized a variant of PNA78 that contains two point mutations (MUT PNA78) and used it as a specificity control along with a "TAT alone" control.
After incubation with K562 cells, PNA-chromatin complexes were isolated by binding to streptavidin-conjugated magnetic beads. The DNA was purified for sequence identification by quantitative PCR. To help us more precisely quantitate the extent of PNA entry into the nucleus, in parallel we collected a portion of the cells from each treatment, stained with the DRAQ5 livecell nuclear stain, and inspected them under confocal microscopy to determine nuclear entry efficiency. The results (Fig. 2B) show that, although the two PNAs and TATare taken up by cells with a similar efficiency, only WT PNA78 interacts with its target sequence within the γ-globin promoter. These data assure us that WT PNA78 has target binding specificity with the endogenous γ-globin promoter in vivo.
PNA Conjugated with a Minimum Activation Domain (AD) Alters Transcriptional Activity in K562 Cells. We next addressed whether PNA78 can be used to alter γ-globin transcription levels. We first utilized a transient assay, transfecting a γ-globin luciferase reporter into K562 cells followed by exposure of the cells to TAT, PNA78/NLS, or PNA78/TAT. Although TAT alone has no effect on the basal activity of the reporter, PNA78/NLS exerts a mild, and PNA78/TAT a stronger, superactivation effect on its expression (Fig. S2A) . Mutation of the target site on the γ-promoter negated its ability to be superactivated by PNA78/TAT; however, the basal activity of the γ-promoter is dramatically impaired (Fig. S2B) , suggesting that the DNA sequence complimentary to PNA78 encodes an important γ-promoter element.
We therefore examined whether the potential of WT PNA78/ TAT to alter transcriptional activity in vivo can be enhanced by linking it to an activator motif. The VP2 minimal AD is a highly acidic 16 amino acid sequence (MLGDFDLDMLGDFDLD) derived from the herpes simplex virus C terminus transactivation domain of VP16 (27) . This artificial transactivator is very potent in vitro when linked to a DNA-binding domain (28) . We linked this amino acid sequence to PNA78/TAT at its 5′ domain to yield VP2/PNA78/TAT but saw little effect on the γ-globin/luciferase reporter in transfected K562 cells beyond that seen with PNA78/ TAT, likely due to the limits of using the already highly active γ-globin promoter as our test. As a result, we tested an artificial luciferase reporter plasmid containing four tandem repeats of PNA78 target sequence upstream of the minimal SV40 promoter and find that the transcriptional activity increases by 2.3-fold in K562 cells treated with VP2/PNA78/TAT compared to nontreated cells, a stronger effect than seen with PNA78/TAT and not observed at all in 293T cells (Fig. S2C) . We conclude that the attachment of a transactivation domain to the PNA78/TAT molecule enhances its ability to activate transcription in the K562 fetal-like erythroid environment.
PNA-AD Changes the Endogenous Globin Expression Pattern in Mouse
Bone Marrow Cells. Although encouraging, these tests had been directed at a nonchromatinized DNA target promoter that is already highly active prior to any treatment. Additional questions are whether a different activation domain might work better than VP2, and whether the placement of biotin (at the amino terminus of the VP2 moiety) might have interfered with its transactivation function. In any case, the ultimate assessment would be to test whether the PNA constructs can activate the γ-globin promoter in an erythroid cell that has already switched off its expression in favor of adult ß-globin. We addressed this in two ways.
Because an appropriate human adult erythroid cell line (i.e., ß-on, γ-off) is not available for this type of test, for our first approach we used a line of mouse bone marrow cells engineered to carry a yeast artificial chromosome that contains the complete human ß-like globin locus (ß-YAC) (29) . These adult bone marrow cells have shut off human fetal γ-globin expression and solely express human adult ß-globin (in addition to the endogenous mouse adult ß-globin). The large ß-YAC is properly controlled during murine development in that human γ-globin is expressed in the yolk sac but switches expression to human ß-globin at the same time as the endogenous mouse ß-globin (30) . The fact that these cells are responsive to a known γ-globin inducer (5-azacytidine) (29) makes them particularly appealing for our experiments.
To investigate whether PNA78 attached to an activation domain can reactivate the endogenous γ-globin gene in these cells, we compared its expression in cells treated with two different minimal AD attached to WT PNA78: the previously mentioned VP2, and another minimal activation domain, ATF14 (CGSDALDDFDLDML), which is also highly acidic and has been shown to be a promising candidate as an artificial transcription factor in vitro and in vivo (31) . In addition, to address whether the relative position of the AD and biotin may affect its transactivational ability, we generated two PNA chimeric variants with ATF14: one (analogous to our PNA/VP2 construct) with the biotin at the 5′ end (amino terminus) of the molecule (Bio-ATF/PNA78/TAT), or one with the biotin inserted between ATF and PNA78 (ATF-Bio/PNA78/TAT).
After treatment, cells were harvested and mRNA extracted for RT-qPCR anslysis. The results (Fig. 3A and Fig. S3) show that, although VP2/PNA78/TAT increases γ-globin levels about 2-fold, ATF-Bio/PNA78/TAT is the most effective at increasing γ-globin expression, attaining a sevenfold increase in comparison to cells treated with PNA78/TATalone. It is of interest that placement of the biotin is critical, as placing it at the extreme 5′ end (Bio-ATF/ PNA78/TAT) interferes with its ability to maximally activate γ-globin expression. Importantly, we also find that γ-globin protein, which is not detectable in the untreated cells, is expressed in ATF-Bio/PNA78/TAT cells in the cytoplasm (Fig. 3B) .
PNA-AD Induces γ-Globin Expression Primary Adult Human Cells.
These results compelled us to perform a decisive test of the chimeric PNA molecule's ability to stimulate γ-globin expression by testing human mobilized peripheral blood CD34 þ cells. When incubated in a two-step serum-free culture system, these progenitors differentiate to phenotypically and morphologically mature erythroid cells (Fig. S4 ). Changes in cell surface expression are already apparent between days 2-4 of culture (Fig. S5A) , and the onset of adult ß-globin RNA and protein expression begins by day 2 (Fig. S5 B and C) . As a result we used peripheral blood CD34 þ cells cultured for 2 d for our test.
We included a mismatched PNA78 variant (ATF-Bio/MUT-PNA78/TAT) that was designed based on MUT-PNA (Fig. 2) as an additional negative control. Purified CD34 þ cells were cultured, treated at the end of day 2 with the various PNA chimeras or with no PNA, and harvested 16 h later for analysis. The results show that only cells treated with ATF-Bio/WT-PNA78/TAT increase γ-globin expression (by almost fivefold compared to untreated cells) (Fig. 4A) , and that this leads to γ-globin protein accumulation solely in those cells (Fig. 4B) . Flow cytometric analysis of streptavidin-FITC-positive (i.e., PNA-positive) cells not only demonstrates a high level of PNA incorporation into the cultured CD34 þ cells, but also confirms that cell death caused by PNA (measured by dual monitoring of FITC+/7-amino-actinomycin positive) is always below 0.5% (Fig. 4C) . Expression profiles of phenotypic markers (CD34, CD36, CD235a, and CD71) are unaltered as well (Fig. S6) , demonstrating that there is no erythroid differentiation abnormality caused by PNA treatment.
We conclude that a chimeric peptide nucleic acid molecule, linked to cell entry/localization and activation amino acid sequences, can be designed to selectively bind and directly activate transcription of a specific endogenous target gene with minimal toxicity in murine bone marrow-derived and (most critically) in primary human cells.
Discussion
We have established that PNAs can be used to effectively target specific gene expression/reactivation by embedding it within two protein domains. One, the TAT sequence, facilitates PNA entry to any living cell via macropinocytosis and further enables the molecule to reach the nucleus and recognize its desired sequence in chromatin. Cell entry could be detected under confocal microscopy as soon as 2 h post-PNA treatment and chromatin association could be monitored by magnetic pull-down and quantitative analysis. When linked to a second protein (transactivation) domain, particularly ATF14, the chimeric PNA is able to reactivate its specific target γ-globin gene expression in vivo in engineered mouse bone marrow cells that contain the complete human β globin locus and in primary human CD34 þ cells isolated from peripheral blood. This embedded chimeric PNA (ecPNA) design is unique in that it incorporates three functional components that can be efficiently synthesized together within one small and stable delivery package: a highly effective transcriptional activation domain (the acidic ATF14 amino acid sequence), an efficient cell/ nuclear entry moiety (the TAT amino acid sequence in its D-isomeric form), and a specific targeting sequence (PNA78).
The optimized ecPNA incorporates several significant properties into its final design. First, we avoid the limitations that follow from a triplex-forming design, focusing instead on a mixed singlestrand PNA sequence to enable strand invasion at a range of sites at the γ-globin promoter. The ability to have a number of choices turns out to have been critical, as not all PNA molecules bind equally well to the promoter in vitro, nor do they all effectively discriminate their target to the same extent. Second, the addition of a biotin to the PNA enables us to readily follow its cell entry and the effectiveness of its subcellular localization, particularly as we rely on live-cell imaging for our analyses. The biotin also provides us with a tag for quantitative assessment of in vitro DNA binding and in vivo chromatin association, both of which rely on unique assays developed for these analyses. Third, as expected from other studies, the TAT sequence is critical for successful cell/nuclear entry that retains a high level of cell viability due to the avoidance of transfection/electroporation protocols. Fig. 3 . PNA78 conjugated to a minimal activation domain reactivates silent γ-globin expression in vivo in mouse adult bone marrow cells (MBC) containing the human βYAC. Cells were treated with each modified PNA78 molecule (PNA78/TAT, VP2/PNA78/TAT, Bio-ATF/PNA78/TAT, ATF-Bio/PNA78/TAT), TAT alone, or buffer (no PNA) and analyzed 16 h after PNA treatment. (A) Expression profile of γ-globin levels in MBC-βYAC cells analyzed by quantitative RT-PCR (three biological replicates analyzed in triplicate) (*p < 0.05; **p < 0.01). PNA entry as monitored by confocal microscopy for a typical experiment is shown in Fig. S3. (B) MBC-βYAC cells were treated with buffer (no PNA) or ATF-Bio/PNA78/TAT and analyzed by confocal microscopy 36 h later by fixing and staining with DAPI (blue) and an anti-human γ-globin protein antibody linked to Alexa 568 (red). K562 cells were also stained and served as a positive control for γ-globin protein detection (arrowheads).
Fourth, the inherent stability of the ecPNA is further enhanced by the use of D-isomeric amino acids. Consistent with this, we find that ATF-Bio/PNA78/TAT persists in K562 cells for over 2 wk after a single 2-h exposure (Fig. S7) . Finally, transactivation modules (VP16 or ATF14), added to the non-TATend of the PNA, are not equivalent in their effects. It is particularly striking that the placement of the biotin tag also alters the effectiveness of the transcriptional activation.
We observe, with no toxicity in human CD34 þ cells, efficient cell entry, chromatin association, and transcriptional effects on γ-globin expression using a concentration of 10 μM. At this concentration, the TAT peptide has no cellular toxicity as tested by cell leakage of cell lines and primary erythrocytes (32) . PNAs have also been tested for toxicity after injection into mice and, under maximal dosage (100 mg∕Kg) with repeated administration, were considered nontoxic as major organ functions were normal and no irreversible damage was detected (33) . PNA itself is also low-immunogenic in mice (34) . These results place PNA at a great potential advantage as a therapeutic compound.
In the present case, to assure direct access to the appropriate cell type, rather than injection it might be envisioned that bone marrow be removed and enriched for CD34 þ cells, treated with ecPNA ex vivo, and then transplanted back. Two additional aspects of hemoglobin biology are encouraging for therapy of hemoglobinopathies. First, for sickle cell disease, it is not necessary that any reagent stimulate levels of HbF production to 100%, as levels of 20% (or even less; ref. 35 ) are clinically adequate (36) . Second, ecPNAs may at least provide a suitable baseline of γ-globin expression that can then be augmented by more conventional approaches (e.g., hydroxyurea or butyrate). For example, a pulsed butyrate regimen was shown to work best with patients who already exhibited a slightly higher baseline level (≥2%) of HbF production (37) .
In an earlier study (38) , the level of γ-globin expression was increased in K562 cells using triple helix-forming PNA targeted to a homopurine region at the −300 region of γ-globin promoter. However, this study was not a true reactivation test, and neither site-specific binding in vivo nor efficiency of cell/nuclear entry were monitored. In addition, amino acid sequences were not incorporated into the PNA design to enable optimal transport into the cell or the nucleus, nor to activate transcription. This study thus relied on electroporation of the PNA into the cell and on the ensuing triplex structure enabling RNA transcription. As a result, cell viability was compromised.
Because the use of triplex-forming PNA requires homopurine in the target sequence and partially requires the use of base analogues, it is not optimal for general targeting of DNAs because it thereby limits the range of design and the number of potential DNA-binding sites. It was because of these limitations to the general applicability of our study that we focused on a single-strand, nontriplex, PNA design as our starting point.
Our work shows that single-strand PNA can be used as a precise gene-activating tool in vivo. By embedding it within a cell/ nuclear entry domain and a transactivation domain, it can specifically reactive the expression of a normally repressed gene in vivo, thus providing a powerful yet nontoxic treatment for hemoglobin disorders or for any other maladies that may be alleviated by activation of a target gene.
Materials and Methods
Magnetic Pull-Down Assay. We developed a unique assay to monitor specific binding of PNA molecules to their cognate DNA site. Two nanograms of 32 P-labeled double-stranded DNA oligonucleotide (designed at regions of the γ-promoter centered at each of the four PNA target sites) was incubated with various molar excess (0-1,000×) of PNA at 37°C overnight in a final volume of 15 μL with 10 mM Tris and 1 mM of EDTA. The resultant material was incubated with equal amount of Dynabeads M280-streptavidin (DYNAL Biotech) for 15 s in 25°C. Beads had been prepared by washing twice with BW (Fig. S8) . FITC+/7-AAD+ (i.e., percent dead cell) results are also shown for CD34 þ cells treated with ATF-Bio/MUT-PNA78/TAT or ATF-Bio/WT-PNA78/TAT.
(binding/washing) buffer (10 mM Tris, pH7.5, 1 mM EDTA, 2.0 M NaCl). The beads were pulled down with a Dynal MPC-S magnetic particle concentrator and washed twice with BW buffer. Samples were finally suspended in 50 μL BW buffer, and radioactivity was counted for 10 min in a scintillation counter to yield the average cpm taken for each sample, which was then divided by the cpm of the input (1 μL of the radio-labeled oligo).
Chromatin Binding/Association Assay. Because the PNA/DNA interaction is not protein-based, we developed a unique chromatin association assay that does not utilize antibodies, but rather relies on the biotin moiety in the PNA molecule as a tag for its isolation with streptavidin beads. The final protocol incorporates elements of chromatin (39) and biotinylated protein (40) immunoprecipitation protocols. PNA 78/TAT or MUT PNA 78/TAT were added to 10 7 K562 cells to a final concentration of 10 μM. After 36 h, a portion of the cells were analyzed and quantified for PNA incorporation efficiency by confocal analysis of live cells (as above), and the rest were harvested and cross-linked with 0.4% formaldehyde (Fisher Scientific, F79-500) for 10 min in room temperature then quenched by addition of glycine in the final concentration of 0.125 M for another 10 min. Cells were then washed twice in cold PBS, pelleted at 3000 rpm, and suspended in 500 μL SDS buffer (50 mM Tris at pH 8.1, 0.5% SDS, 100 mM NaCl, 5 mM EDTA, and protease inhibitors) and incubated 10 min on ice. Cells were then pelleted by centrifugation and resuspended in 1.6 mL immunoprecipitation (IP) buffer (0.3% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH8.1, 167 mM NaCl, and protease inhibitor) and disrupted by sonication (power 4, 21% duty, 30 s each time for 10 times with 2-min pulse on ice) yielding genomic DNA fragments of ∼1;000 bp. Lysates were collected at 13,000 rpm for 30 min and diluted 1∶5 in IP buffer and incubated with 40 μL streptavidin MagneSphere Paramagnetic particles (Promega cat. no. Z5481) for 2 h. Magnetic Particle Concentrator (Dynal MPC-S) was used to collect the MagneSphere and its bound material, which was washed five times with LiCl buffer (100 mM Tris pH8.0, 500 mM LiCl, 1% NP-40, 1% deoxycholic acid). Beads were finally resuspended in 150 μL 300 mM NaCl at 65°C overnight followed by incubation at 42°C for 2 h with 20 μL proteinase K (20 mg∕mL). DNA was purified by phenol/chloroform extraction and resuspended in 20 μL ddH 2 O.
Details for other methods are included in the SI Text.
